
Claims

1. A compound of formula (I):




(I)

wherein R^1 is H or -CH_3; and


R^2 is H or F;

or a pharmaceutically acceptable amide, carbamate or salt thereof, including a salt of such amide or carbamate.

2. The compound as claimed in claim 1, wherein the compound is a compound of formula (Ia) or (Ib):



(Ia)




(Ib)


or a pharmaceutically acceptable amide, carbamate or salt thereof, including a salt of such amide or carbamate;

preferably the compound is the compound of formula (Ia) or a pharmaceutically acceptable amide, carbamate or salt thereof, including a salt of such amide or carbamate.


3. The compound as claimed in claim 1 or 2, wherein the compound is selected from the group consisting of




,



,







, and

and pharmaceutically acceptable amides, carbamate and salts thereof, including salts of such amides or carbamates.

4. The compound as claimed in claim 1, wherein the compound is




or




or a pharmaceutically acceptable amide, carbamate or salt thereof, including a salt of such amide or carbamate.

5. The compound as claimed in claim 1, wherein the compound is




or



or a pharmaceutically acceptable amide, carbamate or salt thereof, including a salt of such amide or carbamate.

6. The compound as claimed in claim 1, wherein the compound is 4-(2-{2-[3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl]-5-chlorophenoxy}ethyl)-N,N,1,5-tetramethyl-1H-pyrazole-3-carboxamide:



,

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 6, together with a pharmaceutically suitable carrier.

8. The composition as claimed in claim 7 which also contains a further therapeutic agent.

9. A compound as claimed in any one of claims 1 to 6, or a composition as claimed in claim 7 or claim 8, for use as a medicament.

10. Use of compound as claimed in any one of claims 1 to 6 or the composition as claimed in claim 7 or 8 for the manufacture of a medicament for the prevention or treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect.

11. The use as claimed in claim 9 or 10, wherein the disease or disorder is selected from the group consisting of hyperproliferative disorders, viral infections, neurological diseases, ischemia, osteoporosis, diabetes, autoimmune diseases and inflammatory diseases.

12. The use as claimed in claim 10 or 11, wherein the disease or disorder is a hyperproliferative disorder, and wherein the hyperproliferative disorder is cancer.

13. The use as claimed in claim 12, wherein the cancer is colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma (such as B-cell lymphoma or disuse large B-cell lymphoma), leukemia (such as AML) or neuroblastoma**.**

14. The use as claimed in claim 12, wherein the cancer is a haematologic malignancy (such as a lymphoma, and in particular a B-cell lymphoma (e.g. high grade mantle zone lymphoma, follicular lymphoma, plasmablastic lymphoma, diffuse large B-cell lymphoma and Burkitt's lymphoma), a myeloma (e.g multiple myeloma) or a leukaemia (e.g. chronic lymphocytic leukaemia, AML and B-acute lymphocytic leukaemia)) or a solid-tumour (such as brain, lung, breast, prostate, ovary, colorectal, gallbladder, kidney or liver cancer, or a neuroblastoma (for example a retinoblastoma, a glioblastoma, a small cell lung carcinoma or an astrocytoma)).

15. The use as claimed in claim 10 or 11, wherein the disease or disorder is a enteroviral infection (for example a picornaviral infection, such as a rhinovirus (HRV, also known as the common cold), poliovirus, foot-and-mouth disease virus, coxsackievirus, hepatitis A virus or enterovirus 71 infection) or a retroviral infection (for example lentivirus infections (such as HIV infection)).

16. The use as claimed in claim 10 or 11, wherein the disease or disorder is selected from the group consisting of the common cold, hand-foot- and mouth disease, polio-like syndrome, flaccid paralysis, herpangina, acute hemorrhagic conjunctivitis, nonspecific febrile illnesses, rashes, upper respiratory tract disease, pericardial effusion, insulin-dependent diabetes (IDDM), Sjogren's syndrome, myocarditis (inflammation of the heart), pericarditis (inflammation of the sac surrounding the heart), meningitis (inflammation of the membranes that line the brain and spinal cord), pancreatitis (inflammation of the pancreas), severe neurological disease in children, foot-and-mouth disease, hepatitis A, and acquired immunodeficiency syndrome.

17. A kit of parts comprising: (a) a first pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 6 and a pharmaceutically acceptable carrier; and (b) a second pharmaceutical composition comprising a further therapeutic agent.